Advertisement
Screener

Traws Pharma, Inc. (TRAW) Net Income (Loss) Attributable to Noncontrolling Interest

1.8 / 5 stars · 32/91 Roast Me

Traws Pharma, Inc. Net Income (Loss) Attributable to Noncontrolling Interest

Traws Pharma, Inc. (TRAW) reported Net Income (Loss) Attributable to Noncontrolling Interest of $163.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-27.

Discontinued › Income Statement

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2020-03-27

  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-12-31 was $0.00.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-09-30 was $326.00K.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2018-06-30 was -$163.00K.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2015-12-31 was $0.00.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2018 was $163.00K.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2015 was -$44.00K.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2014 was -$113.00K.
  • Traws Pharma, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2013 was -$13.00K.
Period endNet Income (Loss) Attributable to Noncontrolling Interest 3 monthNet Income (Loss) Attributable to Noncontrolling Interest 3 month as first filedNet Income (Loss) Attributable to Noncontrolling Interest 6 monthNet Income (Loss) Attributable to Noncontrolling Interest 6 month as first filedNet Income (Loss) Attributable to Noncontrolling Interest 9 monthNet Income (Loss) Attributable to Noncontrolling Interest 12 monthNet Income (Loss) Attributable to Noncontrolling Interest 12 month as first filed
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27
$326.00K
derived: sum of 2 quarters · filed 2020-03-27
$163.00K
derived: sum of 3 quarters · filed 2020-03-27
$163.00K
10-K · filed 2020-03-27
-$163.00K
10-K · filed 2019-04-01
2018-09-30$326.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$163.00K
derived: sum of 2 quarters · filed 2019-11-12
$163.00K
10-Q · filed 2019-11-12
2018-06-30-$163.00K
10-Q · filed 2019-08-14
$163.00K
10-Q · filed 2018-08-14
-$163.00K
10-Q · filed 2019-08-14
$163.00K
10-Q · filed 2018-08-14
2015-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-29
$0.00
derived: sum of 2 quarters · filed 2017-03-29
-$20.00K
derived: sum of 3 quarters · filed 2017-03-29
-$44.00K
10-K · filed 2017-03-29
2015-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14
-$20.00K
derived: sum of 2 quarters · filed 2016-11-14
-$44.00K
10-Q · filed 2016-11-14
-$64.00K
derived: sum of 4 quarters · filed 2016-11-14
2015-06-30-$20.00K
10-Q · filed 2016-08-15
-$44.00K
10-Q · filed 2016-08-15
-$64.00K
derived: sum of 3 quarters · filed 2016-08-15
-$93.00K
derived: sum of 4 quarters · filed 2016-08-15
2015-03-31-$24.00K
10-Q · filed 2016-05-11
-$44.00K
derived: sum of 2 quarters · filed 2016-05-11
-$73.00K
derived: sum of 3 quarters · filed 2016-05-11
-$100.00K
derived: sum of 4 quarters · filed 2016-05-11
2014-12-31-$20.00K
10-K · filed 2015-03-30
-$49.00K
derived: sum of 2 quarters · filed 2015-11-12
-$76.00K
derived: sum of 3 quarters · filed 2015-11-12
-$113.00K
10-K · filed 2016-03-28
2014-09-30-$29.00K
10-Q · filed 2015-11-12
-$56.00K
derived: sum of 2 quarters · filed 2015-11-12
-$93.00K
10-Q · filed 2015-11-12
-$106.00K
derived: sum of 4 quarters · filed 2015-11-12
2014-06-30-$27.00K
10-Q · filed 2015-08-13
-$64.00K
10-Q · filed 2015-08-13
-$77.00K
derived: sum of 3 quarters · filed 2015-08-13
2014-03-31-$37.00K
10-Q · filed 2015-05-15
-$50.00K
derived: sum of 2 quarters · filed 2015-05-15
2013-12-31-$13.00K
10-K · filed 2015-03-30
-$13.00K
10-K · filed 2015-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alzamend Neuro, Inc. (ALZN)United States$0.009B
Imunon, Inc. (IMNN)United States$0.008B-0.56
SOLIGENIX, INC. (SNGX)United States$0.008B
FibroBiologics, Inc. (FBLG)United States$0.009B-0.27
EXICURE, INC. (XCUR)United States$0.008B-1.54
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B